Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients (pts) with locally advanced, k-ras-mutated rectal cancer (LARC): A phase I/II trial SAKK 41/08.
Roger Von Moos
Consultant or Advisory Role - Roche
Honoraria - Bayer Schering Pharma
Research Funding - Roche/Genentech
Dieter Koeberle
No relevant relationships to disclose
Sabina Schacher
No relevant relationships to disclose
Stefanie Hayoz
No relevant relationships to disclose
Ralph C. Winterhalder
No relevant relationships to disclose
Arnaud Roth
Consultant or Advisory Role - Bayer
Gyorgy Bodoky
Consultant or Advisory Role - Bayer Schering Pharma; Lilly; Roche
Honoraria - Amgen; Bayer Schering Pharma
Panagiotis Samaras
Honoraria - Bayer; Roche
Martin D Berger
No relevant relationships to disclose
Daniel Rauch
No relevant relationships to disclose
Piercarlo Saletti
No relevant relationships to disclose
Ludwig Plasswilm
No relevant relationships to disclose
Peter Thum
No relevant relationships to disclose
Urs R. Meier
No relevant relationships to disclose
Pu Yan
No relevant relationships to disclose
Paola Izzo
No relevant relationships to disclose
Dirk Klingbiel
No relevant relationships to disclose
Daniela Baertschi
No relevant relationships to disclose
Kathrin Zaugg
No relevant relationships to disclose